<DOC>
	<DOCNO>NCT02754076</DOCNO>
	<brief_summary>The study 's primary objective evaluate safety tolerability BMN 250 administer subject MPS IIIB via ICV reservoir catheter evaluate impact BMN 250 cognitive function patient MPS IIIB assess Development Quotient .</brief_summary>
	<brief_title>A Treatment Study Mucopolysaccharidosis Type IIIB</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Individuals eligible participate Part 1 study must meet following criterion : Has deficient NAGLU enzyme activity Screening . Blood NAGLU enzyme activity collect analyze centrally . Is ≥ 1 &lt; 11 year age ( least 1 3 subject Part 1 must ≥ 1 &lt; 6 year age ) Has present signs/symptoms consistent MPS IIIB ; individual present signs/symptoms disease ( eg , sibling know patient ) , determination eligibility discretion BioMarin medical monitor conjunction site investigator . Written inform consent parent legal guardian assent subject , require Has ability comply protocol requirement , opinion investigator Individuals eligible participate Part 2 study must meet following criterion : Participated meet protocol requirement transition Study 250901 participate Part 1 Study 250201 Written inform consent parent legal guardian assent subject , require Individuals meet follow exclusion criterion ineligible participate Part 1 study : Has receive stem cell , gene therapy ERT MPS IIIB Has contraindication neurosurgery ( eg , congenital heart disease , severe respiratory impairment , clot abnormality ) Has contraindication MRI scan ( eg , cardiac pacemaker , metal fragment chip eye , aneurysm clip brain ) Has history poorly control seizure disorder Is prone complication intraventricular drug administration , include patient hydrocephalus ventricular shunt Has receive investigational medication within 30 day prior Baseline visit schedule receive investigational drug course study Has medical condition extenuate circumstance , opinion investigator , might compromise subject 's ability comply protocol requirement , subject 's wellbeing safety , interpretability subject 's clinical data . Is pregnant time study Individuals meet follow exclusion criterion ineligible participate Part 2 study : Has receive stem cell , gene therapy ERT MPS IIIB Has contraindication neurosurgery ( eg , congenital heart disease , severe respiratory impairment , clot abnormality ) Has contraindication MRI scan ( eg , cardiac pacemaker , metal fragment chip eye , aneurysm clip brain ) Is prone complication intraventricular drug administration , include patient hydrocephalus ventricular shunt Has receive investigational medication within 30 day prior Baseline visit schedule receive investigational drug course study Has medical condition extenuate circumstance , opinion investigator , might compromise subject 's ability comply protocol requirement , subject 's wellbeing safety , interpretability subject 's clinical data . Is pregnant time study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Sanfilippo Syndrome Type B</keyword>
</DOC>